Management of rheumatoid arthritis.
D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use; D001171:Arthritis, Juvenile / Q000503:physiopathology; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D001379:Azathioprine / Q000627:therapeutic use; D002738:Chloroquine / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005258:Felty Syndrome / Q000188:drug therapy; D006046:Gold / Q000627:therapeutic use; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007937:Leukapheresis; D008171:Lung Diseases / Q000150:complications; D008221:Lymphoid Tissue / Q000528:radiation effects; D008727:Methotrexate / Q000627:therapeutic use; D010396:Penicillamine / Q000627:therapeutic use; D010956:Plasmapheresis; D011878:Radiotherapy; D012216:Rheumatic Diseases / Q000188:drug therapy; D012459:Salicylates / Q000627:therapeutic use; D012859:Sjogren's Syndrome / Q000188:drug therapy; D013122:Spinal Diseases / Q000150:complications; D014657:Vasculitis / Q000188:drug therapy
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D012459:Salicylates; D006886:Hydroxychloroquine; D006046:Gold; D002738:Chloroquine; D003520:Cyclophosphamide; D010396:Penicillamine; D001379:Azathioprine; D008727:Methotrexate